Nasdaq Biotechnology Ishares ETF IBB

$141.30 +1.07 (0.76%)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
P/E (trailing)
—
P/E (forward)
—
Profit margin
—
Debt to equity
—

Trading

Volume
552,023
Avg volume
—
Day's range
$140.40 – $141.78
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone
415-670-2000

Latest news

Stocktwits

cert Nov 1, 6:44 PM 0 replies
SGL_FGHI Oct 31, 4:11 PM
$TGTX $XBI $IBB --- Yesterday, before the market opened, $SNY released its Q3 2026 earnings report. During the earning call and press briefings, Sanofi's CFO Francois Roger explicitly stated that SNY would target larger acquisitions “larger than its historical range of $2 billion to $5 billion” because late-stage phase 3 and commercial-ready assets “are more expensive.” CFO Roger and CEO Belen Garijo outlined a highly disciplined, multi-layered M&A framework designed to aggressively rebuild SNY’s pipeline before the 2030s. Roger highlighted 3 specific operational criteria for any upcoming acquisitions: (1) eliminating “white spaces” in immunology and neurology, (2) shifting away from early-stage “moonshots,” and (3) maintain “financial bolt-on” metrics. TGTX aligns strongly with ALL of SNY’s newly defined operational criteria.
2 replies
SGL_FGHI Oct 31, 5:06 AM
$TGTX $XBI $IBB Yes or No? On 10/30/2026, close was $61.18 and 50-day moving average $55.33, meaning currently trading roughly 10.6% above the 50-day average. The $54.80 - $55.33 zone serves as the primary line of dynamic support. A bounce off this line would confirm the medium-term uptrend remains intact. For shorts, the optimal technical cue is to wait for a daily close below $55.33 on heavy volume. As of 10/30/2026 the 200-day moving average is $43.81. B/c the stock is trading at $61.18, it sits roughly 39.6% above its long-term baseline – a highly extended strong macro uptrend. For longs, $43.81 is the macro “line in the sand” -- even if a major pullback occurs, if TGTX stays above this level, the primary, multi-month bull market remains intact. Shorts are counting on a “mean reversion” pull back toward this line; however, b/c the gap between the current price and the 200-day line is so large (about 40%), any short entry right now will be fighting powerful INSTITUTIONAL momentum.
1 replies
BiotechSwings Oct 31, 12:57 AM
Friday split tells you where the strength lives imo $XBI closed 155.98, down about 1.1% on the day but still up about 2% in five sessions, while $IBB closed 217.61, down only about 0.1% and up about 3.9% in five sessions big names held the line and small names gave a little back, that is watchlist weather into Monday, not a reason to chase anything into the weekend
0 replies
BiotechSwings Oct 30, 9:29 PM
Week ended with biotech split right down the middle imo $XBI closed near 155.98, down about 1.1% from 157.79 $IBB closed near 217.61, down about 0.1% from 217.86. Big names held the line while smaller names gave ground $REGN was the star of the session, up about 12% after Q3 revenue hit 5.12 billion, up 36%, with EPS at 20.07. Dupixent sales and Eylea HD did the lifting, and the quarter read like a name firing on all cylinders $ILMN went the other way, down about 19% to near 235.99 after revenue of 1.13 billion came in just under the 1.15 billion consensus, even with an EPS beat. The sequencing story is still intact imo, and a washout like that just rebuilds the watchlist Monday starts with a live one. $INO got FDA approval after the close for Voceryq, its first approved product, with shares up 215% in extended trading. TGTX earnings land Monday Nov 2 as well
0 replies
TearsForFear Oct 30, 7:53 PM
$IBRX Wrong ! Gridlock is best outcome! Mkts will rally especially biotech like $XBI and $IBB with all the great earnings from BP like $LLY and $MRK (make some BCG)
2 replies
JFais Oct 30, 7:14 PM
$IBB quietly breaking out 🧐 Commercial-stage bio is the place to be (hat tip to Premie)
0 replies
DidYouReadThis Oct 30, 7:05 PM
#eyecare #healthcare #Only #for2027: What #percent of the wet age related macular degeneration do you anticipate $OTLK to take? $REGN $ABBV $IBB #Congrats #Outlook on #FDAApproval!
0 replies